Adverts

Open Access Articles- Top Results for Deslorelin

Deslorelin

</th></tr></th></tr>
Deslorelin
File:Deslorelin.svg
Systematic (IUPAC) name
(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide
Clinical data
Trade names Ovuplant
AHFS/Drugs.com International Drug Names
implant / Inhalation
Pharmacokinetic data
Excretion renal
Identifiers
57773-65-6 7pxN
QH01CA93
PubChem CID 25074999
UNII TKG3I66TVE 7pxN
ChEMBL CHEMBL2365665 7pxN
Chemical data
Formula C64H83N17O12
1282.45 g/mol
 14pxN (what is this?)  (verify)

Deslorelin acetate is an injectable gonadotropin releasing hormone super-agonist (GnRH agonist) also known as an LHRH agonist. It stops the production of sex hormones (testosterone and oestrogen).

Deslorelin Acetate is marketed by Peptech with the brand name Ovuplant.[1] It is currently approved for use in veterinary medicine and is used to induce ovulation in mares as part of the artificial insemination process. It is also used to stabilize high-risk pregnancies, mainly of livestock. Unlike other GnRH agonists, which are mainly used to inhibit luteinizing hormone and follicle-stimulating hormone by their ultimate downregulation of the pituitary gland, Deslorelin is primarily used for the initial flare effect upon the pituitary, and its associated surge of LH secretion.

Pharmacokinetics

Deslorelin is a synthetic analogue of a naturally occurring luteinising-hormone releasing hormone (LHRH). Bioavailability is almost complete.

Clinical trials

Deslorelin was successfully trialed in the US and was approved for veterinary use under certain circumstances. In Europe, it was approved for use in equine assisted reproduction.[2]

It is also being trialed in humans to study its efficacy in treatment of breast cancer in women,[3] and in treating precocious puberty and congenital adrenal hyperplasia in male and female children.[4]

As of August 2011 this drug was not approved for general use in the US, other than within approved clinical trials. Orphan drug status has been designated in the US, though approval had not been issued as of 2011.[5]

References